From Regulatory Approvals to Patents: Cross-Domain Linking for Cardiovascular Device Traceability
arXiv:2606.28353v1 Announce Type: cross Abstract: Linking FDA-approved medical devices to their underlying United States Patent and Trademark Office (USPTO) patents enables critical applications such as recall root-cause analysis, M&A-driven IP discovery, and technology trajectory mapping. However, this cross-domain entity linking task remains unexplored due to severe *semantic gaps*: FDA documents focus on clinical outcomes, while patents describe technical mechanisms, yielding minimal lexical overlap. We formalize medical device-patent linking as a challenging cross-domain entity linking pro
The increasing complexity of medical device innovation and the growing need for robust regulatory oversight and intellectual property management are driving demand for advanced analytical tools.
This development offers a novel approach to cross-domain entity linking, enhancing the traceability of medical devices from clinical approval to underlying intellectual property, which impacts risk management and strategic R&D.
The ability to accurately link regulatory approvals with patents will improve recall analysis, facilitate M&A due diligence for IP assets, and provide clearer insights into technology trajectories within the medical device sector.
- · Medical device manufacturers
- · Regulatory bodies (e.g., FDA)
- · Intellectual property analysts
- · AI/ML research in information retrieval
- · Companies with opaque IP portfolios
- · Inefficient recall processes
Improved transparency and accountability in the medical device industry.
Accelerated innovation through better understanding of market-approved patent landscapes.
Potential for new regulatory frameworks that leverage AI-driven IP and product traceability.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.AI